Dexcom "Continued Strong Performance is Positive... BUT Overvalued Stock Price is a Concern"

[Asia Economy Reporter Park Jihwan] Mirae Asset Securities announced on the 12th that Dexcom has continued its streak of strong performance by recording record-high sales for the third consecutive quarter. However, it also noted that the recently surged stock price may be somewhat overvalued.

Researcher Kim Choonghyun of Mirae Asset Securities said, "In the fourth quarter results last year, Dexcom achieved record-high sales for the third consecutive quarter, exceeding market expectations." Sales increased by 23% compared to the previous year. It is expected that the strong performance will continue this year as well. The company's guidance anticipates a sales increase of 15-20%.

Dexcom is a medical device company that provides blood glucose monitoring equipment for diabetes patients and healthcare professionals. Researcher Kim analyzed, "The diabetes management ecosystem is continuously strengthening and expanding the accessible market, although there are concerns about intensified competition with ABT's Libre." He added that the market growth potential remains attractive. The penetration rate among insulin-intensive therapy patients in the U.S., the company's main market, is only 30%, and steady new patient inflow is being driven by strengthened marketing targeting doctors and patients, which is also positive.

Researcher Kim emphasized, "This year, the global launch of the next-generation G7 is scheduled. The mass production know-how secured from G6 and the FDA approval of Omnipod 5, an insulin patch compatible with G7 and artificial pancreas systems, are expected to aid the stable market penetration of G7."

He also stated, "Recently, by enhancing software capabilities and strengthening connectivity with other devices and solution providers, Dexcom is increasing its moat." Representative examples include artificial pancreas solutions combined with insulin pumps, real-time APIs, and App in App features that allow integration with other apps and data.

The current stock price is analyzed to be overvalued with a 12-month forward price-to-sales ratio (P/S) of 15 times, compared to 10 times for peers. However, he noted, "The recent stock price correction has significantly alleviated valuation pressure (previous high of 22 times)."

This content was produced with the assistance of AI translation services.